Approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. Approved the re-appointment of Mr. Shri Laxminarayana Moondra ....

Profit growth above 25%EBITDA margin expansionRelated-party transactionsResults View source PDF Explain this filing

NATCAPSUQ · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.5%Reaction day

₹169.99

prior close

₹160.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-2.9% vs market

Pharmaceuticals peers, median of 162sector-0.5%-3.1% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.7

10m

+2.5

15m

+2.5

30m

+1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.5-0.6-2.9-0.5-3.1

Next day

-7.1-1.7-5.3-1.2-5.9

-7.8-0.7-7.2-1.5-6.4

-7.1-0.4-6.7-1.6-5.5

-8.6+0.4-9.0-1.1-7.5

-7.3+0.4-7.8-1.3-6.0

-8.2+0.3-8.5-0.7-7.5

15d

-5.3+5.5-10.8+1.3-6.6

-10.4+4.6-15.0+2.6-12.9

-13.5+5.3-18.8+5.3-18.8

+24.1+11.6+12.6+6.8+17.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Natural Capsules Limited reported strong FY2026 results with standalone revenue of Rs 17,377 lakhs (up 3.5% YoY) and net profit of Rs 1,121 lakhs (up 67% YoY). Consolidated revenue stood at Rs 18,720 lakhs with net profit of Rs 1,707 lakhs (up 37% YoY). The Board approved re-appointment of Whole-time Director Mr. Laxminarayan Moondra for 3 years, appointed M/s. Mallya & Mallya as Internal Auditor and Mr. Akshay Dutta as Company Secretary. The company allotted 25,000 equity shares upon ESOP exercise, increasing paid-up capital to Rs 10.41 crore. Statutory auditors P. Chandrasekar LLP issued an unmodified (clean) opinion. One manufacturing unit had temporary shutdown from December 26 due to regulatory issues but resumed from January 30, 2026.

Likely market impact

Strong profit growth exceeding 25% signals operational efficiency gains. The clean audit opinion removes key risks for investors. Share capital dilution from ESOP exercise is minimal at 0.24%. Overall, positive development for shareholders with robust bottom-line growth.